PriceTargets.com logo

Bolt Biotherapeutics - BOLT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.50
  • Forecasted Upside: 600.00%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.50 As of 12/20/2024 06:15 PM ET
▼ -0.0035 (-0.70%)

This chart shows the closing price for BOLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bolt Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BOLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLT

Analyst Price Target is $3.50
▲ +600.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $8.00 and a low forecast of $1.00. The average price target represents a 600.00% upside from the last price of $0.50.

This chart shows the closing price for BOLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Bolt Biotherapeutics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024HC WainwrightReiterated RatingNeutral
8/15/2024HC WainwrightReiterated RatingNeutral
5/15/2024Leerink PartnersReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Neutral
5/15/2024GuggenheimReiterated RatingBuy ➝ Neutral
5/15/2024Stifel NicolausReiterated RatingBuy ➝ Hold$6.00 ➝ $1.50
5/14/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
8/8/2023Stifel NicolausLower Target$7.00 ➝ $6.00
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00
5/12/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform
3/30/2023HC WainwrightReiterated RatingBuy$8.00
1/24/2023Morgan StanleyLower TargetEqual Weight$5.00 ➝ $3.00
10/4/2022HC WainwrightInitiated CoverageBuy$8.00
8/11/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$8.00 ➝ $4.00
5/17/2022Morgan StanleyLower TargetEqual Weight$5.00
5/13/2022Stifel NicolausLower Target$16.00 ➝ $13.00
1/6/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
12/9/2021Leerink PartnersReiterated RatingBuy
12/6/2021Stifel NicolausBoost TargetBuy$19.00 ➝ $34.00
12/6/2021JonestradingReiterated RatingBuy$45.00
11/24/2021JonestradingReiterated RatingBuy$45.00
11/10/2021Leerink PartnersLower TargetOutperform$35.00 ➝ $33.00
9/24/2021JonestradingInitiated CoverageBuy$45.00
8/16/2021Leerink PartnersBoost TargetOutperform$34.00 ➝ $35.00
5/17/2021Leerink PartnersLower TargetOutperform$37.00 ➝ $33.00
4/6/2021Leerink PartnersBoost TargetOutperform$36.00 ➝ $37.00
3/2/2021Morgan StanleyInitiated CoverageOverweight$45.00
3/2/2021Leerink PartnersInitiated CoverageOutperform$36.00
3/2/2021Stifel NicolausInitiated CoverageBuy$40.00
3/2/2021GuggenheimInitiated CoverageBuy$42.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 35 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 39 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Bolt Biotherapeutics logo
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $0.50
Low: $0.49
High: $0.52

50 Day Range

MA: $0.61
Low: $0.50
High: $0.68

52 Week Range

Now: $0.50
Low: $0.49
High: $1.56

Volume

69,985 shs

Average Volume

166,667 shs

Market Capitalization

$19.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Bolt Biotherapeutics?

The following sell-side analysts have issued research reports on Bolt Biotherapeutics in the last year: Guggenheim, HC Wainwright, Leerink Partners, Leerink Partnrs, and Stifel Nicolaus.
View the latest analyst ratings for BOLT.

What is the current price target for Bolt Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for Bolt Biotherapeutics in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 600.0%. HC Wainwright has the highest price target set, predicting BOLT will reach $8.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $1.00 for Bolt Biotherapeutics in the next year.
View the latest price targets for BOLT.

What is the current consensus analyst rating for Bolt Biotherapeutics?

Bolt Biotherapeutics currently has 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BOLT, but not buy more shares or sell existing shares.
View the latest ratings for BOLT.

What other companies compete with Bolt Biotherapeutics?

Other companies that are similar to Bolt Biotherapeutics include Agenus, Fortress Biotech, SAB Biotherapeutics, Curis and Molecular Templates. Learn More about companies similar to Bolt Biotherapeutics.

How do I contact Bolt Biotherapeutics' investor relations team?

Bolt Biotherapeutics' physical mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The company's listed phone number is 650-665-9295 and its investor relations email address is [email protected]. The official website for Bolt Biotherapeutics is www.boltbio.com. Learn More about contacing Bolt Biotherapeutics investor relations.